MEDIROM Healthcare Technologies Regains Compliance With NASDAQ Continued Listing Requirements
MEDIROM Healthcare Technologies Regains Compliance With NASDAQ Continued Listing Requirements
MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan ("MEDIROM" or the "Company"), today announced that on June 1, 2023, the Nasdaq Hearing Panel (the
总部位于日本的整体医疗保健公司（“MEDIROM” 或 “公司”）MEDIROM Healthcare Technologies Inc.（纳斯达克股票代码：MRM）今天宣布，2023年6月1日，纳斯达克听证小组（
MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan ("MEDIROM" or the "Company"), today announced that on June 1, 2023, the Nasdaq Hearing Panel (the "Panel") notified the Company that it has regained compliance with the net income standard set forth in Nasdaq Listing Rule 5550(b)(3) and the periodic filing requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1), as evidenced by the filing of the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2022 on May 30, 2023. The Panel also advised that the Panel's oversight process of the Company is now closed. For more information regarding the Company's compliance with Nasdaq's continued listing requirements, please see the press release of the Company dated May 24, 2023, a copy of which was furnished as Exhibit 99.1 to a report on form 6-K filed by the Company with the SEC on May 24, 2023.
总部位于日本的整体医疗保健公司（“MEDIROM” 或 “公司”）MEDIROM Healthcare Technologies Inc.（纳斯达克股票代码：MRM）今天宣布，2023年6月1日，纳斯达克听证小组（“小组”）通知公司，它已重新遵守纳斯达克上市规则第5550（b）（3）条规定的净收入标准以及纳斯达克上市规则中规定的继续上市的定期申报要求 5250 (c) (1)，公司于2023年5月30日提交的截至2022年12月31日财年的20-F表年度报告就证明了这一点。专家小组还告知，该小组对公司的监督程序现已结束。有关公司遵守纳斯达克持续上市要求的更多信息，请参阅公司2023年5月24日的新闻稿，该新闻稿的副本作为公司于2023年5月24日向美国证券交易委员会提交的6-K表报告的附录99.1提供。
译文内容由第三方软件翻译。